<DOC>
	<DOCNO>NCT00653549</DOCNO>
	<brief_summary>To compare single-dose bioavailability Torsemide tablets Demadex</brief_summary>
	<brief_title>Bioavailability Study Torsemide Tablets Under Fasting Conditions</brief_title>
	<detailed_description>To compare single -dose bioavailability Par Torsemide tablets 20mg Roche Demadex 1*20mg tablet fasting condition .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Torsemide</mesh_term>
	<criteria>Subjects enrol study member community large . The Recruitment do radio , newspaper Anapharm Inc. Anapharm Website advertisement . Subjects must meet follow criterion order include study . Subjects male / female , smoker nonsmoker , 18 year age old . Subjects read , sign , date Informed Consent form prior study procedure . Subjects must complete screening procedure within 28 day prior administration study medication . Breast feed female subject . Any clinically significant abnormality find medical screening . Subjects BMI â‰¥30 Any Clinically significant gastrointestinal pathology ( e.g . chronic diarrhea , inflammatory bowel disease ) unresolved gastrointestinal symptom ( e.g . diarrhea , vomit ) , susceptible interfere absorption drug . Clinically significant illness within 4 week prior administration study medication Abnormal laboratory test judge clinically significant . ECG abnormality ( clinically significant ) ( PR interval great 225ms ) ; vital sign abnormality ( systolic blood pressure low 90 140 mmHg , diastolic blood pressure low 60 95 mmHg , heart rate le 60 bpm ) screening . History allergic reaction torsemide sulfonylurea ( e.g . tolbutamide , chlorpropamide , glyburide gliclazide ) relate drug ( e.g . furosemide , bumetanide , sulfabenzamide , sulfacetamide , sulfathiazole , sulfadiazine , sulfamethoxazole , sulfasalazine , sulfisoxazole dapsone ) . Any food allergy , intolerance , restriction special diet , opinion Medical Sub Investigator , could contraindicate subject 's participation study . Positive urine drug screen screen . Positive test hepatitis B , hepatitis C , HIV screen . Positive urine pregnancy test screening . ( performed female subject ) Use investigational drug participation investigational study within 30 day prior administration study medication . Donation plasma ( 500 mL ) within 7 day donation significant loss whole blood ( 450 mL ) within 56 day prior administration study medication . History significant alcohol abuse within six month screen visit indication regular use two unit alcohol per day ( 1 Unit = 150 mL wine 360 mL beer 45 ml alcohol 40 % ) History drug abuse use illegal drug : Use soft drug ( marijuana , pot ) within 3 month screen visit hard drug ( cocaine , phencyclidine [ PCP ] crack ) within 1 year screen visit . Subjects take prescription medication within 14 day prior administration study medication counter product within 7 day prior administration study medication , except topical product without systemic absorption . Female subject childbearing potential unprotected sexual intercourse non sterile male partner ( i.e . male sterilized vasectomy al least 6 month ) within 14 day prior study drug administration . The Acceptable method contraception : Condom+ spermicide ( within 14 day prior study drug administration ) Diaphragm + spermicide ( within 14 day prior study drug administration . Intrauterine contraceptive device ( place al least 4 week prior study drug administration ) Subjects take drug know induce inhibit hepatic drug metabolism within 30 day prior administration study medication . ( examples inducer : barbiturate , carbamazepine , phenytoin , glucocorticoid , rifampin , rifabutin ; examples inhibitor : antidepressant , cimetidine , diltiazem , erythromycin , ketoconazole , MAO inhibitor , neuroleptic , verapamil , quinidine ) Subjects undergone clinically significant surgery within 4 week prior administration study medication . Any reason , opinion investigator , would Prevent subject participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Torsemide Tablets</keyword>
	<keyword>fast</keyword>
</DOC>